A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors Abstract #2190

Introduction: Retrospective studies showed that changes in plasma chromogranin A (CgA) might predict change in tumor burden in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients.
Aim(s): The aim of this prospective study was to compare the association between changes in plasma CgA and changes in tumor burden on CT in GEP-NET patients with residual disease.
Materials and methods: We included 239 patients with a CT followed by at least one additional CT between 1 and- 24 months later. Change in tumor size was defined and categorized by RECIST1.1. An event was defined as CgA measured within 6 weeks of a CT. In addition, in a post-hoc analysis an event was defined as a CgA measured 3-6 month prior to the CT. A 25% change in CgA discriminated between increased, unchanged or decreased plasma CgA levels. Patients were included in Denmark, Norway and Sweden from December 2010 to December 2013.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: Gitte Dam
Keywords: gep-net, ct, cga, correlation

To read results and conclusion, please login ...

Further abstracts you may be interested in

#3001 Early Response Assessment for Prediction of Overall Survival after Peptide Receptor Radionuclide Therapy
Introduction: PRRT response assessment is performed using RECIST, yet functional assessment using 68Ga-DOTATATE PET/CT and plasma CgA might give additional information about prediction of overall survival (OS).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing
#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
#2935 Prior Surgical Resection and Ga-68-DOTANOC PET/CT Imaging-Based Parameters: Do These Impact Outcomes in Grade II Gastroentero-Pancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: Grade 2 GEP-NETs have inherent tumor heterogeneity seen with positive expression of somatostatin (SSTR) and glucose (GLUT) receptors. Prior surgical resection and imaging parameters on Ga-68 DOTANOC PET/C are well-established variable impacting prognosis in well-differentiated grade 1 NETs. Since the degree of differentiation is variable in Grade 2 NETs, these parameters have not been studied.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Ameya Puranik
#2917 Quantification of Intratherapeutic SPECT/CT for Lutetium-177-DOTATOC PRRT in Neuroendocrine Tumors
Introduction: In PRRT for NET, feasibility of lesion uptake quantification in Lu-177-DOTATOC SPECT/CT for therapy monitoring remains unclear.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Markus Galler
Authors: Galler M, Schatka I, Buch F, Bluemel S, ...
#2973 Robustness of Radiomic Features in 68Ga-DOTATOC PET/CT: A Monocentric Experience for Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NET) are a heterogeneous group of malignancies with varied histology, localization and behaviour.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Virginia Liberini